+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyloidosis Treatment Market by Treatment Type (Pharmacological Treatment, Stem Cell Transplantation, Supportive Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Drug Class, Amyloidosis Type - Global Forecast 2025-2030- Product Image
Amyloidosis Treatment Market by Treatment Type (Pharmacological Treatment, Stem Cell Transplantation, Supportive Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Drug Class, Amyloidosis Type - Global Forecast 2025-2030- Product Image
Sale

Amyloidosis Treatment Market by Treatment Type (Pharmacological Treatment, Stem Cell Transplantation, Supportive Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), End User, Drug Class, Amyloidosis Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888733
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Amyloidosis Treatment Market presents both complexity and opportunity for senior executives seeking resilient growth in the life sciences sector. This market is distinguished by evolving therapeutic modalities, intricate global supply chains, and a shift toward patient-centric care models—all requiring strategic foresight and adaptive commercialization.

Market Snapshot: Amyloidosis Treatment Market

The Amyloidosis Treatment Market grew from USD 5.70 billion in 2024 to USD 6.13 billion in 2025. It is expected to continue growing at a CAGR of 7.35%, reaching USD 8.74 billion by 2030. Growth is fueled by innovations addressing rare disease pathology, a rising focus on molecularly targeted therapies, and expanding adoption in both mature and emerging regions. Increased awareness and advances in diagnostic accuracy have amplified treatment demand, while strategic investments in R&D, digital health, and specialized care pathways steadily reshape patient outcomes and market positioning.

Scope & Segmentation

This report delivers a deep-dive evaluation of the amyloidosis treatment landscape, highlighting diversified technology platforms, care pathways, and regional adoption patterns. Segmentation includes:

  • Treatment Types: Pharmacological treatments, stem cell transplantation, supportive therapy
  • Key Drug Classes: Alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, TTR silencers, TTR stabilizers
  • Representative Drugs: Melphalan, lenalidomide, daratumumab, bortezomib, carfilzomib, ixazomib, inotersen, patisiran, acoramidis, tafamidis
  • Routes of Administration: Intravenous, oral, subcutaneous
  • End User Settings: Home care, hospital, specialty clinic
  • Amyloidosis Subtypes: AA, AL, hereditary ATTR, wild-type ATTR
  • Regions: Americas (US, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (multiple countries), Asia-Pacific (including China, India, Japan, Australia)
  • Company Coverage: Pfizer Inc., Alnylam Pharmaceuticals, Johnson & Johnson (Janssen Biotech, Inc.), Ionis Pharmaceuticals, BridgeBio Pharma, Prothena Corporation

Coverage also extends to technological enablers such as digital health platforms, predictive analytics, and adaptive clinical trial frameworks that enhance detection, monitoring, and value demonstration across global markets.

Key Takeaways for Decision-Makers

  • The shift from broad-spectrum chemotherapy toward molecularly targeted therapies is reshaping standards of care. These innovative approaches aim for higher specificity and improved tolerability, expanding opportunities for precision medicine in rare disease management.
  • Advanced diagnostic and monitoring technologies, including noninvasive imaging and robust biomarker discovery, are accelerating earlier detection and supporting real-time therapy adjustments, directly impacting treatment efficacy and patient experience.
  • Strategic collaborations between biopharma, academic institutions, and contract research organizations are strengthening innovation pipelines, while digital health integration is driving new models for care adherence and patient engagement.
  • The introduction of US import tariffs in 2025 has catalyzed changes across supply chains, encouraging realignment toward domestic manufacturing and prompting companies to reassess pricing, inventory controls, and supplier relationships to sustain access and margin protection.
  • Regional market adoption varies significantly, reflecting differences in clinical infrastructure, reimbursement frameworks, and regulatory agility. Established markets benefit from centralized health technology assessments, while emerging economies focus on affordability and supply chain resilience.

Amyloidosis Treatment Market: Tariff Impact

The 2025 US import tariffs have increased raw material and operational costs across several drug classes, especially for alkylating agents and proteasome inhibitors. Biopharma companies and smaller innovators responded by negotiating with domestic suppliers, reconfiguring production strategies, and undertaking cost-control initiatives. This led to incremental price adjustments and has shaped the overall approach to market access and reimbursement, particularly in high-impact therapeutic segments. In response to these supply-side pressures, some firms have accelerated moves to oral formulations and localized manufacturing.

Methodology & Data Sources

This report is grounded in a rigorous, multi-phased methodology. The secondary research phase incorporated in-depth analysis of peer-reviewed literature, clinical trial databases, regulatory filings, and industry disclosures. Primary research was conducted with expert stakeholders—hematologists, neurologists, pharmacologists, and patient advocates—to validate emerging trends, market dynamics, and real-world barriers. Continuous quality control and data triangulation provided reliability and actionable depth to every finding.

Why This Report Matters

  • Leverage segmented analysis to inform research, investment, or market entry strategies in amyloidosis therapeutics.
  • Benchmark innovation trends and evaluate the competitive landscape across global and regional players.
  • Anticipate the impact of regulatory changes, supply chain challenges, and evolving patient expectations on operational decisions and future growth planning.

Conclusion

Strategic insights in this report equip industry leaders to navigate rapid therapeutic, regulatory, and market shifts in amyloidosis care. By applying these findings, organizations can optimize growth, maintain resilience, and enhance patient outcomes in a dynamic global landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of RNA interference therapies reshaping hereditary transthyretin amyloidosis treatment landscape
5.2. Expansion of genetic screening programs driving earlier diagnosis and intervention for amyloidosis patients
5.3. Integration of advanced amyloid imaging techniques improving treatment monitoring and patient stratification
5.4. Strategic alliances between biotech firms and large pharmaceutical companies accelerating novel amyloidosis drug development
5.5. Reimbursement challenges and payer policy variations impacting patient access to high-cost amyloidosis treatments
5.6. Emergence of monoclonal antibody therapies targeting misfolded protein aggregates in systemic amyloidosis treatment
5.7. Increasing real-world evidence studies enhancing understanding of long-term efficacy and safety of amyloidosis therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Amyloidosis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Pharmacological Treatment
8.2.1. Alkylating Agents
8.2.1.1. Melphalan
8.2.2. Immunomodulators
8.2.2.1. Lenalidomide
8.2.3. Monoclonal Antibodies
8.2.3.1. Daratumumab
8.2.4. Proteasome Inhibitors
8.2.4.1. Bortezomib
8.2.4.2. Carfilzomib
8.2.4.3. Ixazomib
8.2.5. TTR Silencers
8.2.5.1. Inotersen
8.2.5.2. Patisiran
8.2.6. TTR Stabilizers
8.2.6.1. Acoramidis
8.2.6.2. Tafamidis
8.3. Stem Cell Transplantation
8.4. Supportive Therapy
9. Amyloidosis Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Amyloidosis Treatment Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospital
10.4. Specialty Clinic
11. Amyloidosis Treatment Market, by Drug Class
11.1. Introduction
11.2. Alkylating Agents
11.2.1. Melphalan
11.3. Immunomodulators
11.3.1. Lenalidomide
11.4. Monoclonal Antibodies
11.4.1. Daratumumab
11.5. Proteasome Inhibitors
11.5.1. Bortezomib
11.5.2. Carfilzomib
11.5.3. Ixazomib
11.6. TTR Silencers
11.6.1. Inotersen
11.6.2. Patisiran
11.7. TTR Stabilizers
11.7.1. Acoramidis
11.7.2. Tafamidis
12. Amyloidosis Treatment Market, by Amyloidosis Type
12.1. Introduction
12.2. AA
12.3. AL
12.4. Hereditary ATTR
12.5. Wild-Type ATTR
13. Americas Amyloidosis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Amyloidosis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Amyloidosis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Alnylam Pharmaceuticals, Inc.
16.3.3. Johnson & Johnson (Janssen Biotech, Inc.)
16.3.4. Ionis Pharmaceuticals, Inc.
16.3.5. BridgeBio Pharma, Inc.
16.3.6. Prothena Corporation plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. AMYLOIDOSIS TREATMENT MARKET: RESEARCHAI
FIGURE 26. AMYLOIDOSIS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. AMYLOIDOSIS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. AMYLOIDOSIS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 211. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 214. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 215. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 216. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 217. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 218. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 219. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 224. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 225. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 226. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 227. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 234. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 235. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 236. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 237. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 242. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 243. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 244. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 245. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 246. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 247. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 250. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 251. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 252. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 253. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 256. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 257. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 260. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 261. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 262. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 263. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 274. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 275. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 278. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 279. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 280. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 281. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 282. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2025-2030 (USD MILLION)
TABLE 315. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2024 (USD MILLION)
TABLE 316. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2025-2030 (USD MILLION)
TABLE 317. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 318. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Amyloidosis Treatment market report include:
  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Johnson & Johnson (Janssen Biotech, Inc.)
  • Ionis Pharmaceuticals, Inc.
  • BridgeBio Pharma, Inc.
  • Prothena Corporation plc

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.74 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Amyloidosis Treatment Market by Treatment, by Drug Class, by End-User, and By Region - Product Image

Amyloidosis Treatment Market by Treatment, by Drug Class, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Amyloidosis Treatment - Global Strategic Business Report - Product Image

Amyloidosis Treatment - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market Report 2025 - Product Image

Transthyretin Amyloidosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From

About the Amyloidosis‎ Drug Market

Amyloidosis is a rare endocrine and metabolic disorder caused by the accumulation of abnormal proteins in the body's organs and tissues. Treatment for amyloidosis typically involves a combination of drugs, including chemotherapy, corticosteroids, and immunosuppressants. The amyloidosis drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new drugs. The amyloidosis drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of the disease. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. These companies are focusing on developing new drugs and expanding their product portfolios to meet the growing demand for amyloidosis treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.